Examining the Prognostic Value of Conization and HPV Status in Early Cervical Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the prognostic significance of negative high-risk HPV (HR-HPV) status after conization in women diagnosed with cervical cancer, specifically those with squamous cell carcinoma, adeno carcinoma, adeno-squamous carcinoma, or adenocarcinoma in situ (AIS). The study will also investigate whether conization in women with early-stage cervical tumors (up to Stage I B2) correlates with improved prognosis. By analyzing the relationship between HPV status and residual tumor presence in final pathology, the study seeks to provide insights into treatment outcomes and recurrence rates. The findings could help refine treatment strategies for early-stage cervical cancer patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Age Range: 18-85 years old Cervical cancer stage I B 2(Tumor up to 4 cm FIGO 2018) AIS HPV types before and after conization

Exclusion Criteria:

Pregnant women under 18 years old. Women who refused to continue to be in study. Women that data about HPV types , final pathology or complication are missing.

Where it's running

• Rambam Health Care Center
  Haifa, Israel Recruiting

Study contacts

• Principal investigator: Yoav Siegler, MD — Rambam Health Care Center
• Study coordinator: Yoav Siegler, MD
• Email: yoav.siegler@gmail.com
• Phone: +972528263054

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Shorter pelvic radiotherapy after surgery for cervical or endometrial cancer

  A randomized study tests whether a shorter course of postoperative whole-pelvic radiotherapy can be as safe and effective as the standard longer schedule for women with cervical or endometrial cancer.

  Recruiting Siriraj Hospital · Bangkok, Bangkok · NCT07595224

• Late radiation side effects after postoperative IMRT and brachytherapy for cervical and endometrial cancer

  This project will see how often and how severe late gastrointestinal and urinary side effects are in people with cervical or endometrial cancer who received postoperative IMRT and/or brachytherapy at Tata Memorial Hospital.

  Recruiting Tata Memorial Hospital · Mumbai, Maharashtra · NCT07435623

• Comparing clinic-only versus clinic plus community outreach to offer HPV self-collection for cervical screening in women with HIV

  This project will test whether adding community health worker outreach to clinic services helps more women living with HIV complete HPV self-collection for cervical screening.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Kampala · NCT07428330

• Outcomes for Oligometastatic and Oligorecurrent Cervical Cancer

  This registry will see if adding local treatments such as radiation or surgery to standard systemic therapy helps people with oligo‑metastatic or oligo‑recurrent cervical cancer live longer or avoid progression.

  Recruiting Tata Memorial Hospital · Mumbai, Maharashtra · NCT07400809

• Hyaluronic acid gel spacer to protect nearby organs during cervical cancer radiation

  This pilot tests a hyaluronic acid gel spacer (Barrigel) to see if it helps people with cervical cancer receiving chemoradiotherapy and brachytherapy by creating space between the tumor and nearby organs.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07292818

• Short-course (hypofractionated) versus standard radiotherapy with cisplatin and brachytherapy for locally advanced cervical cancer in Uganda

  This trial tests whether a shorter, higher-dose radiotherapy schedule plus cisplatin and brachytherapy works as well and causes no more serious side effects than the usual longer schedule for women in Uganda with stage IB3–IIIC cervical cancer.

  Recruiting Phase 2 Uganda Cancer Institute · Kampala, Kampala · NCT07276360

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.